HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSCH becomes Proteonomix

This article was originally published in The Rose Sheet

Executive Summary

Biotech firm National Stem Cell Holdings announces name change to Proteonomix and change of trading symbol from NHGI to PROTD, makes official its focus on proteomics and its movement from strict R&D to commercial product development. In July, the company introduced its new cosmeceutical line featuring "unique natural matrix of proteins called Secreted Matrix and Matrix NC-138" through subsidiary Proteoderm, whose first public display of the skin-care products at recent International Anti-Aging Conference in Washington D.C. met with an "encouraging response." Proteoderm has plans for "an extensive array of specialty skin-care products" formulated with its proprietary proteins derived from non-embryonic stem cells," according to the release. Protenomix believes it now is in a position to raise capital in "very challenging financial environment for product commercialization.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel